Risk assessment of systemic sclerosis-associated pulmonary arterial hypertension: cardiac index <i>versus</i> stroke volume index

Pulmonary arterial hypertension (PAH) frequently complicates systemic sclerosis (SSc), with an estimated prevalence of 6.4–9% [1, 2]. Although survival has improved with the advent of PAH-specific therapy, SSc-PAH continues to have poor prognosis, with a 3-year survival of 67% [3]. Current PAH management guidelines highlight the importance of risk stratification in guiding therapy [4]. Footnotes This manuscript has recently been accepted for publication in the European Respiratory Journal . It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article. Conflict of interest: Hussein J. Hassan has nothing to disclose. Conflict of interest: Mario Naranjo has nothing to disclose. Conflict of interest: Brigitte Kazzi has nothing to disclose. Conflict of interest: Traci Housten-Harris has nothing to disclose. Conflict of interest: Steven Hsu has nothing to disclose. Conflict of interest: Aparna Balasubramanian has nothing to disclose. Conflict of interest: Catherine E. Simpson has nothing to disclose. Conflict of interest: Rachel L. Damico has nothing to disclose. Conflict of interest: Todd M. Kolb has nothing to disclose. Conflict of interest: Stephen C. Mathai has nothing to disclose. Conflict of interest: Paul M. Hassoun has nothing to disclose.